Chapter 4.1 188 13. Seifer M, Hamatake RK, Colonno RJ, Standring D. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200465 and lobucavir. Antimicrob Agents Chem 1998;42:3200–3208. 14. Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S, et al. Efficacy of the carbocyclic 2 0 -deoxyguanosine nucleoside BMS 200475 in the woodchuck model of hepatitis B virus infection. Anti microb Agents Chemother 1998;42:3209–3217. 15. Colonno R, Medina I, Lamb C, Genovesi E, Clark J. Maintenance of viral suppression in chronically infected woodchucks with weekly dosing of BMS-200475. Hepatology 1998;28:488A. 16. Colonno RJ, Genovesi EV, Median I, Lamb L, Durham S, Corey L, et al. Long-term therapy with entecavir (BMS-200475) in the wood chuck model of chronic hepatitis infection. Abstract 172 of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. 17. Tsiang M, Rooney JF, Toole JJ, Gibbs C. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863–1869. 18. Wolters LMM, Hansen BE, Niesters HGM, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in chronic hepatitis B patients during lamivudine therapy Liver. 2002 Apr;22(2):121-6 19. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. EUROHEP Pathobiology Group. J Clin Microbiol 1999;37:68–73. 20. Stuyver L, van Geyt C, de Gendt S, van Reybroeck G, Zoulim F, Leroux-Roels G, et al. Line probe assay for monitoring during resis tance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38:702–707. 21. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of Interferon-a therapy. Science 1998;282:103–107. 22. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398–4402. 23. Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Cruz de Castro E, Costa X, et al. Two years of lamivudine therapy in patients with chronic hepatitis B. Analysis of efficacy and emergence of HBV genomic variations (abstract). J Hepatol 2000;2(Suppl):111. 24. Liaw YF, Leung NW, Chang TT, Guan R, Tai D, Ng K, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepa titis B. Gastroenterology 2000;119(1):172–180. 25. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33(6):1527–1532. 26. de Man RA, Wolters LMM, Nevens F, Chua D, Sherman M, Lai CL, et al. A study of oral entecavir given for 28 days in both treatment-naive and pre-treated subjects with chronic hepatitis. Hepatology 2001;34(3):578–582.
Viral dynamics during and after entecavir therapy 189 27. Wolters LMM, Hansen BE, Niesters HGM, Levi-Drummer RS, Neumann AU, Schalm SW, et al. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol 2002 Aug;37(2):253-8. 28. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six-month rando mized dose-ranging study. Gastroenterology 1997;113:1258–1263.